16.3% weight loss in the second phase of the structure obesity pills
Analysts note that this Phase II readout puts aliglipron in line to challenge other oral GLP-1RAs on the market if it has shown Phase III success. Credit: New Africa / Shutterstock.com. Structure Therapy’s oral weight-loss drug, alaniglipron, has led to strong weight loss in a Phase II obesity trial — results that analysts suggest put … Read more
